The effect of disease, functional status, and relapses on the utility of people with multiple sclerosis in the UK

Value in Health

Volumn 10, Issue 1, 2007, Pages 54-60

  Orme, Michelle ^a   Kerrigan, John ^a   Tyas, David ^a   Russell, Nicola ^b   Nixon, Richard ^c  

^a Heron Evidence Development Ltd   (United Kingdom)

^b MS Trust   (United Kingdom)

^c MRC BIOSTATISTICS UNIT   (United Kingdom)

Author keywords

EQ 5D; Multiple sclerosis; Study; Utility

Indexed keywords

ADULT; AGED; ARTICLE; COST UTILITY ANALYSIS; CROSS-SECTIONAL STUDY; DISEASE DURATION; DISEASE SEVERITY; FEMALE; FUNCTIONAL STATUS; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; PRIORITY JOURNAL; QUALITY OF LIFE; QUESTIONNAIRE; RELAPSE; UNITED KINGDOM;

EID: 33846506747     PISSN: 10983015     EISSN: 15244733     Source Type: Journal    
DOI: 10.1111/j.1524-4733.2006.00144.x     Document Type: Article

References (18)

1. Quarles R, Morell P, McFarland H. Diseases involving myelin. In: Siegel G, Agranoff B, Albers R, et al., eds., Basic Neurochemistry, Molecular, Cellular, and Medical Aspects (6th ed.). Philadelphia, PA: Lippincott Williams & Wilkins, 1999.
2. Richards RG, Sampson FC, Beard SM, Tappenden P. A review of the natural history and epidemiology of multiple sclerosis: implications for resource allocation and health economic models. Health Technol Assess 2002;6:1-73.
3. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983 November;33:1444-52.
4. Kobelt G, Berg J, Atherley D, et al. Costs and quality of life in multiple sclerosis a cross-sectional study in the USA. SSE/EFI Working Paper Series in Economics and Finance, 2004. Report no. 594.
5. Rudick R, Antel J, Confavreux C, et al. Recommendations from the National Multiple Sclerosis Society Clinical Outcomes Assessment Task Force. Ann Neurol 1997;42:379-82.
6. Hohol MJ, Orav EJ, Weiner HL. Disease steps in multiple sclerosis: a simple approach to evaluate disease progression. Neurology 1995;45:251-5.
7. Gruenewald DA, Higginson IJ, Vivat B, et al. Quality of life measures for the palliative care of people severely affected by multiple sclerosis: a systematic review. Mult Scler 2004;10:690-704.
8. Brazier J, Deverill M. Obtaining the "Q" in Qalys: a comparison of five multi-attribute utility scales. University of Sheffield: Sheffield Health Economics Group, School of Health and Related Research, 1999 February. Report no. 99/1.
9. Forbes RB, Lees A, Waugh N, Swingler RJ. Population based cost utility study of interferon beta-1b in secondary progressive multiple sclerosis. BMJ 1999;319:1529-33.
10. Parkin D, McNamee P, Jacoby A, et al. A cost-utility analysis of interferon beta for multiple sclerosis. Health Technol Assess 1998;2:iii-54.
11. Association of British Neurologists. Guidelines for the Use of Beta Interferons and Glatiramer Acetate in Multiple Sclerosis. London: Association of British Neurologists, 2001. Available at http://www.theabn.org-documents/msdoc. pdf [Accessed October 11, 2005].
12. How to use EQ-5D. 2006. September 20, 2005. Internet Communication. Available at http://www.euroqol.org/web/users/howtouse.php [Accessed September 20, 2005].
13. Kobelt G, Lindgren P, Smala A, et al. Costs and quality of life in multiple sclerosis An observational study in Germany. HEPAC Health Econ Prev Care 2001;2:60-8.
14. Dolan P, Gudex C. A social tariff for euroqol: results from a UK general population survey. Centre for Health Economics. University of York, 1995. Report no. 138.
15. Currie CJ, McEwan P, Peters JR, et al. The routine collation of health outcomes data from hospital treated subjects in the Health Outcomes Data Repository (HODaR): descriptive analysis from the first 20,000 subjects. Value Health 2005;8:581-90.
16. Mitchell AJ, Benito-Leon J, Gonzalez JM, Rivera-Navarro J. Quality of life and its assessment in multiple sclerosis: integrating physical and psychological components of wellbeing. Lancet Neurol 2005;4:556-66.
17. Khan F, McPhail T, Brand C, et al. Multiple sclerosis: disability profile and quality of life in an Australian community cohort. Int J Rehabil Res 2006;29:87-96.
18. Friedman C, Wyatt J. Evaluation Methods in Biomedical Informatics (Health Informatics) (2nd ed.). New York: Springer-Verlag New York Inc., 2005.